Pharmaceutical Preparations · MA · CIK 875320
Discovers and develops small-molecule drugs and gene-editing therapies for serious diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 27, 2026: 12 sold $76.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $450.95 | $1.1M |
| Mar 13, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $481.79 | $1.1M |
| Mar 11, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1.3M |
| Mar 4, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1.2M |
| Mar 2, 2026 | Liu JoyEVP and Chief Legal Officer | Sell | 892 | $495.96 | $442K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 15,580 | $495.38 | $7.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 5,995 | $496.16 | $3.0M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,498 | $494.33 | $1.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,278 | $488.27 | $1.6M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,725 | $490.54 | $1.3M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,520 | $493.29 | $1.2M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,510 | $487.13 | $1.2M |
| Feb 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $480.31 | $1.1M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 1,725 | $496.95 | $857K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 949 | $491.30 | $466K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 460 | $489.32 | $225K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 400 | $479.75 | $192K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 240 | $482.84 | $116K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 120 | $481.50 | $58K |
| Feb 26, 2026 | Ambrose KristenSVP & Chief Accounting Officer | Sell | 357 | $483.36 | $173K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 12 reputable articles · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗